Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Phase 3

Completed

Conditions: Disorder Related to Bone Marrow Transplantation
Leukemia
Transplantation Infection

Interventions: Drug: Fludarabine
Drug: Busulfan
Drug: Clofarabine
Drug: Thymoglobulin
Procedure: Stem Cell Infusion
Drug: Tacrolimus
Drug: Methotrexate

First Posted Date: 2011-11-15

Last Posted Date: 2021-12-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 256

Registration Number: NCT01471444

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

Phase 1

Completed

Conditions: Lymphoma
Leukemia
Transplantation, Bone Marrow
Transplantation Infection
Blood And Marrow Transplantation

Interventions: Drug: Fludarabine
Drug: Melphalan
Drug: Mycophenolate mofetil
Drug: Tacrolimus
Procedure: Cord Blood Infusion
Drug: Rituximab
Drug: ATG
Drug: Busulfan
Drug: Clofarabine
Radiation: Total Body Irradiation (TBI)

First Posted Date: 2011-11-11

Last Posted Date: 2017-04-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 33

Registration Number: NCT01471067

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

Phase 2

Terminated

Conditions: Metastatic Melanoma
Skin Cancer

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Young Tumor Infiltrating Lymphocytes (TIL)

First Posted Date: 2011-11-10

Last Posted Date: 2016-06-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT01468818

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

T-Cell Depleted Double UCB for Refractory AML

Phase 2

Terminated

Conditions: Acute Myelogenous Leukemia
Refractory Acute Myelogenous Leukemia

Interventions: Drug: Allopurinol
Drug: Fludarabine
Radiation: Total body irradiation
Drug: Cyclophosphamide
Drug: Levetiracetam
Drug: Busulfan
Biological: Umbilical Cord Blood Transplantation
Biological: Interleukin-2

First Posted Date: 2011-11-03

Last Posted Date: 2017-12-28

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 3

Registration Number: NCT01464359

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer

Phase 1

Terminated

Conditions: Metastatic Melanoma
Metastatic Cancer
Metastatic Renal Cancer

First Posted Date: 2011-10-21

Last Posted Date: 2019-01-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2

Registration Number: NCT01457131

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

Phase 1

Completed

Conditions: Glioblastoma
Malignant Glioma
Brain Cancer
Gliosarcoma

Interventions: Biological: Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL
Drug: Aldesleukin
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2011-10-19

Last Posted Date: 2019-08-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 18

Registration Number: NCT01454596

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial

Phase 3

Terminated

Conditions: Scleroderma, Systemic

Interventions: Biological: Peripheral Blood Stem Cells
Drug: Cyclophosphamide
Drug: Mesna
Drug: rATG
Drug: Methylprednisolone
Drug: Filgrastim
Drug: Fludarabine

First Posted Date: 2011-10-04

Last Posted Date: 2020-07-23

Lead Sponsor: Northwestern University

Target Recruit Count: 44

Registration Number: NCT01445821

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia

Phase 1

Completed

Conditions: Acute Myeloblastic Leukemia

First Posted Date: 2011-09-16

Last Posted Date: 2017-04-25

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 55

Registration Number: NCT01435343

Locations: 🇪🇸
Hospital Clínic de Barcelona, Barcelona, Spain
🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸
Hospital Duran i Reynals - ICO L'Hospitalet, Barcelona, Spain

and more 7 locations

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Phase 2

Terminated

Conditions: Post-Transplant Lymphoproliferative Disorder
Recurrent B-Cell Non-Hodgkin Lymphoma
Recurrent Burkitt Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Refractory B-Cell Non-Hodgkin Lymphoma
Refractory Burkitt Lymphoma

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Radiation: Indium In-111 Ibritumomab Tiuxetan
Drug: Mycophenolate Mofetil
Other: Pharmacological Study
Biological: Rituximab
Radiation: Total-Body Irradiation
Radiation: Yttrium Y-90 Ibritumomab Tiuxetan
Drug: Fludarabine

First Posted Date: 2011-09-15

Last Posted Date: 2021-07-20

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT01434472

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies

Phase 2

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Myeloid Leukemia in Remission
Adult Erythroleukemia (M6a)
Adult Nasal Type Extranodal NK/T-cell Lymphoma
Adult Pure Erythroid Leukemia (M6b)
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Blastic Phase Chronic Myelogenous Leukemia

Interventions: Drug: cyclophosphamide
Drug: cyclosporine
Procedure: peripheral blood stem cell transplantation
Radiation: total-body irradiation
Drug: fludarabine phosphate
Drug: busulfan
Procedure: allogeneic hematopoietic stem cell transplantation

First Posted Date: 2011-09-02

Last Posted Date: 2017-05-19

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 43

Registration Number: NCT01427881

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy